Pomalidomide - Author Reply

Ashleigh P Scott^{1

2}, Peter Mollee^{2

3}

Affiliations

Comment

Ashleigh P Scott et al. Leuk Lymphoma. 2019 Apr.

. 2019 Apr;60(4):1105.

doi: 10.1080/10428194.2018.1516884. Epub 2018 Oct 2.

Ashleigh P Scott^{1

2}, Peter Mollee^{2

3}

No abstract available

Comment on

'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.
Scott A, Weber N, Tiley C, Taylor K, Taper J, Harrison S, Chan KL, Stark R, Lee C, Morris K, Ho PJ, Dodds A, Ramanathan S, Ramakrishna R, Watson AM, Auguston B, Kwok F, Quach H, Warburton P, Rowlings P, Mollee P. Scott A, et al. Leuk Lymphoma. 2018 Jun;59(6):1514-1516. doi: 10.1080/10428194.2017.1387911. Epub 2017 Oct 12. Leuk Lymphoma. 2018. PMID: 29022836 No abstract available.
Real world experience with "generic" pomalidomide in relapsed refractory multiple myeloma.
Jandial A, Mishra K, Lad D, Prakash G, Khadwal A, Malhotra P. Jandial A, et al. Leuk Lymphoma. 2019 Apr;60(4):1102-1104. doi: 10.1080/10428194.2018.1508675. Epub 2018 Oct 15. Leuk Lymphoma. 2019. PMID: 30322320 No abstract available.